Sfoglia per AUTORE
RICHARDSON PG
Collezione AOU Città della Salute di Torino

  

Items : 23

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects. in Frontiers in immunology / Front Immunol. 2025 Feb 12;16:1519300. doi: 10.3389/fimmu.2025.1519300. eCollection 2025.
2025
AOU Città della Salute di Torino

Horenstein AL; Faini AC; Morandi F; Ortolan E; Storti P; Giuliani N; Richardson PG; Malavasi F;

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. in Blood cancer journal / Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w.
2024
AOU Città della Salute di Torino

Richardson PG; Perrot A; Mikhael J; Martin T; Beksac M; Spicka I; Capra M; D'Agostino M; Sonneveld P; Bisht K; Fukao T; Zhang R; Tada K; Tekle C; Macé S; Klippel Z; van de Velde H; Moreau P;

Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study. in European journal of haematology / Eur J Haematol. 2024 Mar;112(3):402-411. doi: 10.1111/ejh.14127. Epub 2023 Nov 15.
2024
AOU Città della Salute di Torino

Bakker NA; Thuresson M; Norin S; Abdulhaq H; Larocca A; Mateos MV; Ludwig H; Schjesvold FH; Richardson PG; Sonneveld P;

Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. in Leukemia research / Leuk Res. 2022 Nov;122:106948. doi: 10.1016/j.leukres.2022.106948. Epub 2022 Sep 6.
2022
AOU Città della Salute di Torino

Rawlings AM; Moreau P; Symeonidis A; Martin T; Mikala G; Jelínek T; Bringhen S; Hajek R; Spicka I; Beksac M; van de Velde H; Richardson PG;

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. in Haematologica / Haematologica. 2022 Mar 1;107(3):774-775. doi: 10.3324/haematol.2021.279160.
2022
AOU Città della Salute di Torino

Schjesvold F; Richardson PG; Facon T; Alegre A; Spencer A; Jurczyszyn A; Sunami K; Frenzel L; Min CK; Guillonneau S; Lin PL; Le-Guennec S; Campana F; Van de Velde H; Bensfia S; Bringhen S;

2022
AOU Città della Salute di Torino

Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. in European journal of haematology / Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. Epub 2021 Sep 22.
2022
AOU Città della Salute di Torino

Larocca A; Yagci M; Robak P; Liberati AM; Galli M; Lindsay J; Oriol A; Beksac M; Salomo M; Pavic M; Dürig J; Jenner M; Corso A; Engelhardt M; Sonneveld P; Rodriguez-Otero P; White D; Anderson LD Jr; Moreau P; Weisel K; Schjesvold F; Richardson PG; Vural F; Kanate AS; Jiang R; Grote L; Peluso T; Dimopoulos M;

Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. in British journal of haematology / Br J Haematol. 2022 Feb;196(3):639-648. doi: 10.1111/bjh.17887. Epub 2021 Oct 21.
2022
AOU Città della Salute di Torino

Laubach J; Nadeem O; Mazumder A; Raptis A; Rodriguez-Otero P; Oriol A; Alegre A; Cavo M; Maisel C; Mateos MV; Paner A; Bladé J; Touzeau C; Leleu X; Larocca A; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG;

Melphalan flufenamide for relapsed/refractory multiple myeloma. in Drugs of today (Barcelona, Spain : 1998) / Drugs Today (Barc). 2022 Aug;58(8):407-423. doi: 10.1358/dot.2022.58.8.3367680.
2022
AOU Città della Salute di Torino

Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG;

Melflufen for the treatment of multiple myeloma. in Expert review of clinical pharmacology / Expert Rev Clin Pharmacol. 2022 Apr;15(4):371-382. doi: 10.1080/17512433.2022.2075847. Epub 2022 Jun
2022
AOU Città della Salute di Torino

Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV;

2021
AOU Città della Salute di Torino

Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG;

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9.
2021
AOU Città della Salute di Torino

Laubach JP; Moreb JS; Anderson KC; Raptis A; Mazumder A; Maisel C; Paner A; Alegre A; Hassoun H; Touzeau C; Hiemenz JW; Nadeem O; Leleu X; Rodriguez-Otero P; Cavo M; Bladé J; Larocca A; Oriol A; Richardson PG; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.
2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. in British journal of haematology / Br J Haematol. 2021 Jun;193(6):1105-1109. doi: 10.1111/bjh.17302. Epub 2021 Jan 6.
2021
AOU Città della Salute di Torino

Byrne C; Nordström E; Sonneveld P; Reeves B; Mellqvist UH; Plesner T; Voorhees PM; Bringhen S; Harmenberg J; Obermüller J; Richardson PG;

Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. in Future oncology (London, England) / Future Oncol. 2021 Dec;17(34):4797-4812. doi: 10.2217/fon-2021-0568. Epub 2021 Sep 15.
2021
AOU Città della Salute di Torino

Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA;

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. in British journal of haematology / Br J Haematol. 2021 Aug;194(3):496-507. doi: 10.1111/bjh.17338. Epub 2021 Mar 16.
2021
AOU Città della Salute di Torino

Sezer O; Sonneveld P; Reece D; Rasche L; Moreau P; Mohty M; Merlini G; Lentzsch S; Mateos MV; Leleu X; Leal da Costa F; Kyle RA; Kröger N; Jurczyszyn A; Hungria V; Hájek R; Gay F; Gahrton G; Fernández de Larrea C; Engelhardt M; Dispenzieri A; Einsele H; Dimopoulos MA; Cavo M; Caers J; Badros A; Anderson KC; Van de Donk NWCJ; Zamagni E; et alii...

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. in Haematologica / Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.
2021
AOU Città della Salute di Torino

Schjesvold FH; Richardson PG; Facon T; Alegre A; Spencer A; Jurczyszyn A; Sunami K; Frenzel L; Min CK; Guillonneau S; Lin PL; Le-Guennec S; Campana F; van de Velde H; Bensfia S; Bringhen S;

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. in Journal of clinical medicine / J Clin Med. 2020 Sep 27;9(10):3120. doi: 10.3390/jcm9103120.
2020
AOU Città della Salute di Torino

Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG;

Melflufen for relapsed and refractory multiple myeloma. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2020 Oct;29(10):1069-1078. doi: 10.1080/13543784.2020.1808884. Epub 2020
2020
AOU Città della Salute di Torino

Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG;

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. in The Lancet. Haematology / Lancet Haematol. 2020 May;7(5):e395-e407. doi: 10.1016/S2352-3026(20)30044-2. Epub 2020 Mar 23.
2020
AOU Città della Salute di Torino

Anderson K; Nordström E; Chauhan D; Byrne C; Zubair H; Paba-Prada C; Reeves B; Mellqvist UH; Plesner T; Voorhees P; Bringhen S; Richardson PG; Harmenberg J; Palumbo A; Sonneveld P;

Second primary malignancies in multiple myeloma: an overview and IMWG consensus. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606.
2017
AOU Città della Salute di Torino

Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; et alii...

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.
2016
AOU Città della Salute di Torino

Dimopoulos MA; Sonneveld P; Leung N; Merlini G; Ludwig H; Kastritis E; Goldschmidt H; Joshua D; Orlowski RZ; Powles R; Vesole DH; Garderet L; Einsele H; Palumbo A; Cavo M; Richardson PG; Moreau P; San Miguel J; Rajkumar SV; Durie BG; Terpos E;

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
2016
AOU Città della Salute di Torino

Kumar S; Paiva B; Anderson KC; Durie B; Landgren O; Moreau P; Munshi N; Lonial S; Bladé J; Mateos MV; Dimopoulos M; Kastritis E; Boccadoro M; Orlowski R; Goldschmidt H; Spencer A; Hou J; Chng WJ; Usmani SZ; Zamagni E; Shimizu K; Jagannath S; Johnsen HE; Terpos E; Reiman A; Kyle RA; Sonneveld P; Richardson PG; McCarthy P; et alii...